SIGA TECHNOLOGIES INC 10-Q — AI Bull & Bear Analysis

The Q1 2026 filing reveals a company at a critical crossroads, balancing a massive government-backed backlog against deteriorating operational margins and regulatory setbacks. The financials show a stark contrast between the 'fortress' balance sheet of $145.6 million and a growing quarterly burn rate. While the BARDA contract provides a theoretical ceiling of $630 million, the actual realization of these funds depends on the government's discretion, creating a volatile revenue profile that makes traditional valuation difficult. Ultimately, the investment thesis hinges on whether the current inventory build and the Hikma partnership can offset the loss of the mpox indication and the failure of recent clinical trials. The market must weigh the certainty of the U.S. government's smallpox stockpile requirements against the speculative nature of international commercial growth and new label expansions. SIGA's ability to convert its work-in-process inventory into high-margin revenue will be the primary signal for investors in the coming quarters.